Prot #M14-239: Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

Project: Research project

Project Details

StatusActive
Effective start/end date12/4/1912/4/20

Funding

  • AbbVie Inc. (Prot #M14-239)